🔎 Trials Near Me

Home › Melanoma › Massachusetts › Boston

Melanoma clinical trials in Boston, MA

26 studies for Melanoma are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07751042

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

RecruitingPhase 1/2
  • Tufts Medical Center, Boston
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

RecruitingPhase 2
  • Local Institution - 0124, Boston
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07492680

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

RecruitingPhase 1/2
  • Massachusetts General Hospital Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07288112

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

RecruitingPhase 2
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT04899908

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

RecruitingPhase 1/2
  • Dana Farber Cancer Institute, Boston
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07070232

Cryoablation+Ipilimumab+Nivolumab in Melanoma

RecruitingPhase 2
  • Massachusetts General Hospital Cancer Center, Boston
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT05779423

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute, Boston
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119

Project: Every Child for Younger Patients With Cancer

RecruitingObservational study
  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT06425926

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

RecruitingPhase 1/2
  • Massachusetts General Hospital Cancer Center, Boston
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

RecruitingPhase 1
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT06150664

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

RecruitingPhase 1/2
  • Call for Information (Investigational Site 0026), Boston
6 Months – 17 Years · All sexes · Updated Jul 6, 2026 · NCT02332668

Video Education With Result Dependent dIsclosure

Recruiting
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT05225428

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

RecruitingPhase 1/2
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT05379985

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT03686124

Neoadjuvant Darovasertib in Primary Uveal Melanoma

RecruitingPhase 3
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT07015190

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

RecruitingPhase 2/3
  • Dana Farber, Boston
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT06624644

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

RecruitingPhase 3
  • Massachusetts General Hospital, Boston
  • Beth Israel Deaconess Medical Center (BIDMC), Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Feb 25, 2026 · NCT05549297

ACTengine® IMA203 Combined With mRNA-4203

RecruitingPhase 1
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jan 8, 2026 · NCT06946225

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

RecruitingPhase 2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 to 100 · All sexes · Updated Jan 5, 2026 · NCT05428007

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Oct 8, 2025 · NCT04370587

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Feb 13, 2025 · NCT05669430

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Nov 15, 2024 · NCT04787042

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

RecruitingPhase 2
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Mar 18, 2024 · NCT05280314

About Melanoma

Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.

More about Melanoma on MedlinePlus

Melanoma trials in other cities

Other studies in Boston

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.